Abstract

Liraglutide (Lir) is a glucagon-like peptide-1 receptor agonist that lowers blood sugar and reduces myocardial infarct size by improving endothelial cell function. However, its mechanism has not yet been clarified. Unfolded protein response (UPR) plays an important role in the pathogenesis of myocardial ischemia-reperfusion injury. It determines the survival of cells. Endoplasmic reticulum position protein homologue 2 (CNPY2) is a novel initiator of UPR that also participates in angiogenesis. To this extent, the current study further explored whether Lir regulates angiogenesis through CNPY2. In our article, a hypoxia/reoxygenation (H/R) injury model of human umbilical vein endothelial cells (HUVECs) was established and the effect of Lir on HUVECs was first evaluated by the Cell Counting Kit-8. Endothelial tube formation was used to analyze the ability of Lir to induce angiogenesis. Subsequently, the effect of Lir on the concentrations of hypoxia-inducible factor 1α (HIF1α), vascular endothelial growth factor (VEGF), and CNPY2 was detected by enzyme-linked immunosorbent assay. To assess whether Lir regulates angiogenesis through the CNPY2-initiated UPR pathway, the expression of UPR-related pathway proteins (CNPY2, GRP78, PERK, and ATF4) and angiogenic proteins (HIF1α and VEGF) was detected by reverse transcription-polymerase chain reaction and Western blot. The results confirmed that Lir significantly increased the expression of HIF1α and VEGF as well as the expression of CNPY2-PERK pathway proteins in HUVECs after H/R injury. To further validate the experimental results, we introduced the PERK inhibitor GSK2606414. GSK2606414 was able to significantly decrease both the mRNA and protein expression of ATF4, HIF1α, and VEGF in vascular endothelial cells after H/R injury. The effect of Lir was also inhibited using GSK2606414. Therefore, our study suggested that the CNPY2-PERK pathway was involved in the mechanism of VEGF expression after H/R injury in HUVECs. Lir increased the expression of VEGF through the CNPY2-PERK pathway, which may promote endothelial cell angiogenesis and protect HUVEC from H/R damage.

Highlights

  • Acute myocardial infarction (AMI) is a type of cardiovascular disease that occurs after acute coronary artery occlusion, which results in myocardial hypoxia and necrosis

  • To further validate the effect of Lir on angiogenesis, we examined changes of cell tube formation after H/R injury in human umbilical vein endothelial cells (HUVECs)

  • The results suggested that Lir enhanced the activity and tube formation after H/R injury in HUVECs

Read more

Summary

Introduction

Acute myocardial infarction (AMI) is a type of cardiovascular disease that occurs after acute coronary artery occlusion, which results in myocardial hypoxia and necrosis. After AMI, it is crucial to restore coronary blood supply as soon as possible to mitigate myocardial ischemic injury (Santos-Gallego et al, 2014; Prondzinsky et al, 2018). Reperfusion methods such as percutaneous coronary intervention, thrombolysis, and surgical bypass have successfully restored coronary blood supply and limited the infract size of the myocardium (Boateng and Sanborn, 2013). The coronary no-reflow phenomenon is an independent predictor of persistent myocardial ischemia, ventricular remodeling, and dysfunction after coronary reperfusion (Bouleti et al, 2015; Mazhar et al, 2016; Rezkalla et al, 2017), as it affects immediate and long-term prognosis (Ndrepepa et al, 2010; Choo et al, 2014). The current treatment methods cannot fundamentally solve the problem of myocardial injury, forcing us to explore a new treatment or an adjuvant treatment

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call